Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rapid diagnostic manufacturers like QuidelOrtho pack hundreds of pages with data on FDA approvals, respiratory test demand, and global reagent sales. Parsing those details—and catching when executives sell stock just before a new assay launch—takes time most professionals don’t have. That’s why our SEC page starts where the paperwork ends: delivering QuidelOrtho SEC filings explained simply.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K, and DEF 14A the moment it hits EDGAR, then surfaces what matters. Want the QuidelOrtho quarterly earnings report 10-Q filing without wading through accounting footnotes? Our AI summary highlights respiratory segment margins in seconds. Need QuidelOrtho insider trading Form 4 transactions? Real-time alerts flag every submission, letting you monitor QuidelOrtho executive stock transactions Form 4 before the market reacts. Each filing card links to plain-language explanations—perfect for understanding QuidelOrtho SEC documents with AI.
Beyond form codes, we connect disclosures to questions analysts really ask. The annual report 10-K simplified shows how immunoassay revenue compares to molecular diagnostics, while our QuidelOrtho earnings report filing analysis maps R&D spending to upcoming test launches. The latest QuidelOrtho proxy statement executive compensation reveals how bonuses hinge on regulatory clearances, and our AI notes any red flags. Even sudden supply-chain updates arrive via QuidelOrtho 8-K material events explained. With comprehensive coverage, AI-powered summaries, and Form 4 insider transactions in real time, this page turns dense disclosures into actionable insight—so you can focus on decisions, not document hunting.
QuidelOrtho Corporation furnished a stockholder letter via an 8-K. The letter from President and CEO Brian J. Blaser provides an update on results for the third quarter ended September 28, 2025 and is included as Exhibit 99.1.
The information, including Exhibit 99.1, is being furnished and is not deemed “filed” under the Exchange Act, which means it is not subject to Section 18 liability and is not incorporated by reference into other filings. The report was signed by CFO Joseph M. Busky. QuidelOrtho’s common stock trades on Nasdaq under the symbol QDEL.
QuidelOrtho Corporation reported a quarterly net loss of $733.0 million, largely due to a non-cash goodwill impairment of $700.7 million that eliminated all remaining goodwill. Total revenues were $699.9 million, down from $727.1 million a year ago, as lower Point of Care sales offset growth in Labs and Immunohematology.
Operating results reflected $39.6 million of restructuring, $47.7 million of intangible amortization, and $46.1 million in net interest expense. Year-to-date, the company recorded a net loss of $1,001.1 million and used $26.7 million in operating cash.
QuidelOrtho refinanced its capital structure on August 21, 2025, entering a new Credit Agreement with a $1.15B Term Loan A, $1.45B Term Loan B, and a $700.0M revolver; it repaid prior facilities and ended the quarter with $2.66B in total borrowings and $98.1 million in cash. Segment revenue was led by Labs $373.8M and Point of Care $164.6M. A final judgment related to a supplier dispute required payment of $10.8 million.
QuidelOrtho Corporation furnished an 8-K announcing its financial results for the third quarter ended September 28, 2025, and an earnings conference call. The company will host the call at 2:00 p.m. Pacific Time on November 5, 2025. A press release with the results is furnished as Exhibit 99.1. The information is furnished and not deemed filed under the Exchange Act.
QuidelOrtho (QDEL) reported insider equity activity by EVP of R&D & CTO Jonathan P. Siegrist. On 10/15/2025, 18,656 restricted stock units converted into common stock at $0 per unit. To cover taxes, 6,676 shares were withheld by the issuer at a price of $27.31.
Following these transactions, Siegrist directly holds 11,980 shares of common stock. He also holds 37,314 RSUs that will vest in equal installments on October 15, 2026 and October 15, 2027. Each RSU represents the right to receive one share of QuidelOrtho common stock.
QuidelOrtho (QDEL) reported an insider equity award event. Chief Legal Officer Michelle A. Hodges had 390 restricted stock units vest on October 15, 2025, converting into 390 common shares at $0. To cover tax withholding, 199 shares were withheld at $27.31. Following these transactions, she directly beneficially owned 29,403 common shares.
Ronald Lee Bowman, Chief Human Resources Officer of QuidelOrtho Corporation (QDEL), reported issuance and vesting activity on 09/15/2025. 2,565 restricted stock units (RSUs) vested and were released into common stock. To satisfy tax withholding obligations, the issuer withheld 918 shares (disposed at an effective price of $28.92 per share), leaving 1,647 shares of common stock directly owned by Bowman after the transaction. The filing also shows 5,132 RSUs remain outstanding and will vest in equal installments on 09/15/2026 and 09/15/2027. The Form 4 was signed by an attorney-in-fact on behalf of Bowman on 09/17/2025.
QuidelOrtho Corporation disclosed that it entered into a Credit Agreement dated
FAQ
What is the current stock price of Quidel (QDEL)?
What is the market cap of Quidel (QDEL)?
